Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines

Ujiie, Hideyuki; Shimizu, Takeru; Natsuga, Ken; Arita, Kenji; Tomizawa, Kazuo; Shimizu, Hiroki

doi:10.1111/j.1365-2230.2006.02117.x

Cited by 12 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, symptomatic treatment is the first‐choice therapy for CholU. Nonsedating H1 antihistamines (evidence level A, best practice recommendation) and updosing in nonresponders (evidence level 0, best practice recommendation) are effective in many patients, and there are reports on the efficacy of omalizumab (evidence level B, best practice recommendation) , scopolamine butylbromide (evidence level C) , methantheliniumbromide (evidence level C) , combinations of propranolol, antihistamines, and montelukast (evidence level C) , and treatments and injections with botulinum toxin (evidence level C) . Desensitization protocols involving regular physical exercise (evidence level B) or treatment with autologous sweat have been described in some patients .…”

Section: Cholinergic Urticariamentioning

confidence: 99%

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision

Magerl

Altrichter

Borzova

et al. 2016

Allergy

304

402

View full text Add to dashboard Cite

These recommendations for the definition, diagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous consensus report on physical urticarias and cholinergic urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.These recommendations for the definition, diagnosis, and management of chronic inducible urticaria (CIndU) extend, revise, and update our previous consensus report on physical urticarias and cholinergic urticaria (1), a joint initiative of the EAACI (European Academy of Allergology and Clinical Immunology) Dermatology Section, the GA 2 LEN (Global Allergy and Asthma European Network) task force on urticaria, the EDF (European Dermatology Forum), and UNEV (urticaria network e.V.). Changes to the 2009 consensus report reflect the results of studies published since then. Chronic inducible urticariasChronic inducible urticarias (CIndUs) are a subgroup of chronic urticaria, a group of diseases characterized by the recurrence of itchy wheals and/or angioedema for longer than 6 weeks [ Table 1, (2)]. Most CIndUs present with wheals, angioedema, or both. Within the group of CIndU, symptomatic dermographism/urticaria factitia, cold and heat urticarias, delayed pressure urticaria, solar urticaria, and vibratory angioedema are defined as physical urticarias. Nonphysical CIndUs include cholinergic urticaria, contact urticaria, and aquagenic urticaria. CIndUs, in contrast to chronic spontaneous urticaria (CSU), are characterized by the need for specific triggers for wheals, angioedema, or both of these symptoms to develop. Wheals and angioedema in CIndU patients develop only and reproducibly in response to the trigger stimulus that is specific for their condition (e.g., cold exposure in cold urticaria). CIndU signs and symptoms are usually confined to skin areas that are exposed to the Allergy 71 (2016) 780-802

show abstract

Section: Cholinergic Urticariamentioning

confidence: 99%

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision

Magerl

Altrichter

Borzova

et al. 2016

Allergy

304

402

View full text Add to dashboard Cite

show abstract

“…Kim and Lee [1] state that one may consider sporadic steroid administration when skin eruption occurs in a patient with cross-reaction in various antihistamines and that the use of anti-IgE and desensitization may also be considered if the symptom is severe. However, because using anti-IgE would be difficult considering our patient being only 4 years old, antihistamines were substituted with intranasal local administration of anticholinergic agents for respiratory symptoms such as common cold and scopolamine butylbromide was orally administered for cholinergic skin eruptions [12,13].…”

Section: Discussionmentioning

confidence: 99%

Drug eruption by antihistamine mistaken for chronic urticaria in a child

et al. 2019

View full text Add to dashboard Cite

Although rare, antihistamines can cause adverse effects, including drug-induced eruptions or anaphylaxis. A 4-year-old child visited the pediatric department of a hospital for skin eruptions after administration of antihistamines, (e.g., ucerax [hydroxyzine] or leptizine [levocetirizine]), for cholinergic rashes; he did not have pruritus. Skin prick, intradermal, and drug provocation tests were performed to determine the relationship between the antihistamines and eruptions. Levocetirizine induced wheals in the skin prick test and a rash in the oral drug provocation test. In contrast, ketotifen induced no reaction in the skin prick test but showed a positive reaction in the oral provocation test. Our case report highlights that children can experience the same types of adverse reactions as seen in adults, and cross-reactivity between various antihistamines can occur.

show abstract

“…У пациентов, не отвечающих на терапию антигистаминными препаратами, описаны случаи эффективного применения скополамина бутилбромида [75], метантелиния бромида [76], комбинации пропранолола, антигистаминных препаратов и монтелукаста [77], а также введения ботулинического токсина [78]. Описано также применение высоких доз даназола (600 мг ежедневно) с положительным эффектом, однако низкий профиль безопасности препарата ограничивает его использование [79-81].…”

Section: A R T I C L E I N P R E S Sunclassified

Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Serdotetskova

Danilycheva

Fomina

et al. 2023

Russian Journal of Allergy

View full text Add to dashboard Cite

Chronic induced urticaria (CIndU) is a group of diseases characterized by the occurrence of itchy wheals and/or angioedema in response to specific triggers, such as mechanical irritation, exposure of high and low temperatures, vibration, as well as ultraviolet radiation of various spectrum, appearing for 6 or more weeks. This group of diseases is characterized by a long duration, a significant impact to the patients quality of life, as well as the risk of severe life-threatening reactions. Diagnosis of induced urticaria - patient-safe reproduction of symptoms by exposure to a trigger (temperature, mechanical, etc.). Currently, there are no registered medical devices in the Russian Federation for the threshold diagnosis of most physical forms of urticaria, which makes it difficult to diagnose and dynamically monitor the state of these groups of patients and the response to treatment. The question of therapy with CIndU also remains open, due to the insufficient effectiveness of the recommended and available methods of therapy. This article provides an rewiew of current literature data.

show abstract

Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines

Cited by 12 publications

References 5 publications

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision

Drug eruption by antihistamine mistaken for chronic urticaria in a child

Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Contact Info

Product

Resources

About

Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines

Cited by 12 publications

References 5 publications

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision

Drug eruption by antihistamine mistaken for chronic urticaria in a child

Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Contact Info

Product

Resources

About

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision

The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision